CN102304570B - 用于癌症诊断和治疗的组合物和方法 - Google Patents

用于癌症诊断和治疗的组合物和方法 Download PDF

Info

Publication number
CN102304570B
CN102304570B CN201110214039.XA CN201110214039A CN102304570B CN 102304570 B CN102304570 B CN 102304570B CN 201110214039 A CN201110214039 A CN 201110214039A CN 102304570 B CN102304570 B CN 102304570B
Authority
CN
China
Prior art keywords
mir15
mir16
cll
cells
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110214039.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102304570A (zh
Inventor
卡洛·M·克罗西
乔治·A·卡林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of CN102304570A publication Critical patent/CN102304570A/zh
Application granted granted Critical
Publication of CN102304570B publication Critical patent/CN102304570B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201110214039.XA 2002-11-13 2003-11-12 用于癌症诊断和治疗的组合物和方法 Expired - Fee Related CN102304570B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42586402P 2002-11-13 2002-11-13
US60/425,864 2002-11-13
US46946403P 2003-05-09 2003-05-09
US60/469,464 2003-05-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200380104787 Division CN1719973A (zh) 2002-11-13 2003-11-12 用于癌症诊断和治疗的组合物和方法

Publications (2)

Publication Number Publication Date
CN102304570A CN102304570A (zh) 2012-01-04
CN102304570B true CN102304570B (zh) 2015-01-21

Family

ID=32314611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110214039.XA Expired - Fee Related CN102304570B (zh) 2002-11-13 2003-11-12 用于癌症诊断和治疗的组合物和方法

Country Status (8)

Country Link
US (4) US20040152112A1 (cg-RX-API-DMAC7.html)
EP (1) EP1567007B1 (cg-RX-API-DMAC7.html)
JP (2) JP4939055B2 (cg-RX-API-DMAC7.html)
CN (1) CN102304570B (cg-RX-API-DMAC7.html)
AT (1) ATE546528T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003291433B2 (cg-RX-API-DMAC7.html)
CA (1) CA2504605C (cg-RX-API-DMAC7.html)
WO (1) WO2004043387A2 (cg-RX-API-DMAC7.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE546528T1 (de) 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
EP1713938A2 (en) 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
EP2471924A1 (en) 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
EP2990410A1 (en) * 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
DK1797183T3 (da) * 2004-09-02 2012-10-01 Univ Yale Regulering af onkogener med mikrornas
ES2534300T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
WO2007044057A2 (en) 2005-02-24 2007-04-19 The Ohio State University Research Foundation Methods for quantifying microrna precursors
WO2007016548A2 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
EP1928807A4 (en) * 2005-09-02 2011-05-04 Picobella Llc ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY
US8481505B2 (en) * 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
CA2624531A1 (en) * 2005-10-05 2007-04-19 Carlo M. Croce Wwox gene, vectors containing the same, and uses in treatment of cancer
AU2012238336B8 (en) * 2006-01-05 2014-08-07 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2014203454B2 (en) * 2006-01-05 2016-03-17 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2016203848B2 (en) * 2006-01-05 2017-12-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007081680A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
EP2484782B1 (en) * 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2522748A1 (en) * 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007147067A2 (en) * 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
WO2008036741A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
EP2102341A2 (en) * 2006-12-08 2009-09-23 Asuragen, INC. Mirna regulated genes and pathways as targets for therapeutic intervention
JPWO2008090930A1 (ja) * 2007-01-23 2010-05-20 オリンパス株式会社 癌の診断方法
JP2010516291A (ja) 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性白血病(aml)の診断、予後及び治療のためのマイクロrnaに基づく方法及び組成物
EP2125032A4 (en) 2007-02-20 2011-02-23 Mayo Foundation CANCER TREATMENT WITH VIRAL NUCLEIC ACID
CN101688240A (zh) * 2007-04-10 2010-03-31 国立台湾大学 通过微rna预测癌症患者的治疗后存活预期
CN101827941B (zh) * 2007-04-30 2014-07-16 俄亥俄州立大学研究基金会 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
EP2173911B1 (en) * 2007-07-31 2014-06-18 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP3138926A3 (en) * 2007-09-06 2017-04-05 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
EP2212440A4 (en) * 2007-10-11 2011-04-06 Univ Ohio State Res Found METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF ADENOCARCINOMES OF DISHES
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
WO2009062169A2 (en) 2007-11-09 2009-05-14 The Board Of Regents Of The University Of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
EP2225396A4 (en) * 2007-11-30 2011-03-02 Univ Ohio State Res Found PROFILING AND SCREENING OF MICRO-RNA EXPRESSION IN PERIPHERAL BLOOD IN LUNG CANCER
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20110054009A1 (en) * 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
JP2011517932A (ja) * 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト慢性リンパ球性白血病(ccl)と関連するマイクロrnaシグネチャーおよびその使用
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
JP2012507300A (ja) * 2008-10-30 2012-03-29 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Rnaパターンを評価する方法
GB2465088C (en) * 2008-10-30 2016-01-27 Caris Mpi Inc miRNA expression in the characterisation and classification of cancer
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
US8883995B2 (en) 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements
JP5812491B2 (ja) 2009-10-01 2015-11-11 国立研究開発法人国立がん研究センター 腫瘍治療剤
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
JP2014509852A (ja) 2011-03-07 2014-04-24 ジ・オハイオ・ステート・ユニバーシティ マイクロRNA−155(miR−155)により誘導される変異誘発活性は炎症および癌を結び付ける
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
EP2790735A4 (en) 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
WO2013106766A2 (en) * 2012-01-13 2013-07-18 The Research Foundation Of State University Of New York THERAPEUTIC INDICATIONS OF miR-1291
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CA2879410C (en) 2012-08-20 2018-06-26 National Cancer Center Agent for treating cancer
WO2015067710A2 (en) * 2013-11-06 2015-05-14 Universite De Rennes 1 Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
CN104846086A (zh) * 2015-05-04 2015-08-19 四川大学华西第二医院 血浆miR-15b作为分子标记物在精子产生与功能评估中的应用
CN109295231A (zh) * 2017-11-03 2019-02-01 中国医学科学院基础医学研究所 Nok基因在慢性b淋巴细胞白血病诊断或治疗中的用途
US12551669B2 (en) 2020-07-15 2026-02-17 Biogen Ma Inc. Medical system including two access ports
IL299904B1 (en) 2020-07-20 2026-05-01 Cerebral Therapeutics Inc Liquid catheter device for recording brain status
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode
WO2023249888A1 (en) * 2022-06-21 2023-12-28 Curamir Therapeutics, Inc. Cytarabine-modified mirna for treating cancer
EP4417285B1 (en) * 2023-02-16 2026-07-01 Sartorius BIA Separations d.o.o. PROCESS FOR PURIFICATION OF LIPID NANOPARTICLES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140049A (en) * 1996-11-21 2000-10-31 Genset Detection and early diagnosis of prostate cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP2428570B1 (en) * 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US20050191632A1 (en) * 2002-11-01 2005-09-01 John Byrd Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
ATE546528T1 (de) * 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
JP4230457B2 (ja) 2002-12-18 2009-02-25 サード・ウェーブ・テクノロジーズ・インク 低分子核酸の検出方法
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
KR20050115231A (ko) * 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
US20080045417A1 (en) 2003-10-14 2008-02-21 Jan Weiler Oligonucleotide Microarray

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140049A (en) * 1996-11-21 2000-10-31 Genset Detection and early diagnosis of prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Gene Therapy and Translational Cancer Research";Dang C.V. et al;《Clin Cancer Res.》;19991231(第5期);471-474 *

Also Published As

Publication number Publication date
US20090123533A1 (en) 2009-05-14
CA2504605C (en) 2016-01-19
US8557515B2 (en) 2013-10-15
HK1077475A1 (en) 2006-02-17
ATE546528T1 (de) 2012-03-15
EP1567007A4 (en) 2009-11-11
US9006190B2 (en) 2015-04-14
US20060165659A1 (en) 2006-07-27
WO2004043387A2 (en) 2004-05-27
US20100173319A1 (en) 2010-07-08
AU2003291433A1 (en) 2004-06-03
JP2011225570A (ja) 2011-11-10
US20040152112A1 (en) 2004-08-05
CN102304570A (zh) 2012-01-04
CA2504605A1 (en) 2004-05-27
AU2003291433B2 (en) 2008-05-22
JP4939055B2 (ja) 2012-05-23
US7723035B2 (en) 2010-05-25
JP2006506469A (ja) 2006-02-23
EP1567007B1 (en) 2012-02-22
WO2004043387A3 (en) 2004-11-04
EP1567007A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
AU2003291433B2 (en) Compositions and methods for cancer diagnosis and therapy
CN103028120B (zh) 用于诊断或治疗bcl2相关癌症的组合物和方法
CN101939446B (zh) 人类卵巢癌中的微小rna特征
ES2545383T3 (es) Métodos y composiciones basados en microARN para el diagnóstico, pronóstico y tratamiento de cáncer de mama
HK1077475B (en) Compositions and methods for cancer diagnosis and therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150121

Termination date: 20181112

CF01 Termination of patent right due to non-payment of annual fee